Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

Regulatory

October 4, 2024

Change in the Board of Directors of Egetis Therapeutics

Read more

Regulatory

September 30, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Read more

Regulatory

September 30, 2024

Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million

Read more

Upcoming event

October 25, 2024

Extraordinary general meeting (forms can be found here)

Latest presentation

June 20, 2024

Replay of Triac Trial II topline results webcast

Latest Report

August 22, 2024

Interim report Q2 2024

Calendar and upcoming reports

October 25, 2024

Extraordinary general meeting

November 8, 2024

Interim Report Q3 2024 (7:00am CET)

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]